Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Sponsor: Jonsson Comprehensive Cancer Center
A PHASE1/PHASE2 clinical study on Cutaneous T-Cell Lymphoma Refractory and T-cell-prolymphocytic Leukemia, this trial is actively recruiting participants. The trial is conducted by Jonsson Comprehensive Cancer Center and has accumulated 3 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
3 versions recorded-
Aug 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Mar 2025 — May 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jonsson Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .